Trial date set for Teva's generic COPAXONE patent infringement litigation against Momenta

Mar 2 2011

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that the United States District Court for the Southern District of New York has set a trial date of September 7, 2011 in the Company's ongoing patent infringement litigation against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan Pharmaceuticals, Inc./Mylan Inc./Natco Pharma Ltd. regarding their purported generic versions of COPAXONE® (glatiramer acetate injection).

"We are very pleased to have a trial date as we are confident we will prevail in this litigation," said Richard Egosi, Teva's Chief Legal Officer. "Teva remains committed to vigorously defending its intellectual property rights against infringement."

Source:

Teva Pharmaceutical Industries Ltd.

Posted in: Medical Patent News | Pharmaceutical News

Comments (0)

Suggested Reading

Researchers warn meal delivery apps could undermine global nutrition efforts—here’s how
Discovery solves 67-year-old biochemical mystery about vitamin B1
Patients urged to check packs of blood pressure medicine lercanidipine after labelling error
Cancer immunotherapy effective across all ages despite immune differences
London Lab Live 2025 set to launch as the UK’s flagship event for lab professionals
Both low and moderate-high intensity exercise could help fight against Alzheimer's
Food-as-medicine could save billions in healthcare costs—here’s what’s standing in its way
Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals for development as proprietary combination therapies

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Experimental drug NU-9 shows promise for Alzheimer's and ALS treatment